Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, p.2014 ,
Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, pp.1221-1251, 1982. ,
Osteogenic Sarcoma: A 21st Century Review, Anticancer Research, vol.36, issue.9, pp.4391-4399, 2016. ,
DOI : 10.21873/anticanres.10982
Exomics and immunogenics, OncoImmunology, vol.127, issue.1, p.27817, 2014. ,
DOI : 10.1126/scitranslmed.3003689
URL : http://www.tandfonline.com/doi/pdf/10.4161/onci.27817?needAccess=true
Translational biology of osteosarcoma, Nature Reviews Cancer, vol.34, issue.11, pp.722-757, 2014. ,
DOI : 10.3109/02841869509127199
-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study, OncoImmunology, vol.31, issue.3, p.990800, 2015. ,
DOI : 10.1158/1078-0432.CCR-07-4534
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours, Clinical Sarcoma Research, vol.157, issue.1, p.13, 2016. ,
DOI : 10.1016/S0002-9440(10)64850-X
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res, pp.2110-2119, 2011. ,
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, issue.48, pp.78343-78354, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466103
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, pp.2522-2531, 2005. ,
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005. ,
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.8, pp.1070-80, 2016. ,
DOI : 10.1016/S1470-2045(16)30096-1
Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages, PLoS ONE, vol.12, issue.11, p.80908, 2013. ,
DOI : 10.1371/journal.pone.0080908.s004
URL : https://doi.org/10.1371/journal.pone.0080908
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success, Journal of Clinical Oncology, vol.33, issue.27, pp.3029-3064, 2015. ,
DOI : 10.1200/JCO.2014.59.4895
URL : http://europepmc.org/articles/pmc4979196?pdf=render
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, Journal of Clinical Oncology, vol.33, issue.20, pp.2279-87, 2015. ,
DOI : 10.1200/JCO.2014.60.0734
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms, Mediators of Inflammation, vol.266, issue.14, p.816460, 2015. ,
DOI : 10.1016/j.fsi.2013.07.042
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide incombination with interferon-?, J Exp Clin Cancer Res, vol.33, p.27, 2014. ,
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improvesoverall survival--a report from the Children's Oncology Group, J Clin Oncol Feb, vol.126, issue.4, pp.633-641, 2008. ,
Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer, Cancer Discovery, vol.5, issue.1 ,
DOI : 10.1158/2159-8290.CD-14-0621
Trastuzumab enhanced the cytotoxicity of V??9V??2 T cells against zoledronate-sensitized osteosarcoma cells, International Immunopharmacology, vol.28, issue.1, 2015. ,
DOI : 10.1016/j.intimp.2015.06.002
Hepatocellular carcinoma cell sensitivity to V??9V??2 T lymphocyte-mediated killing is increased by zoledronate, International Journal of Oncology, vol.48, issue.5, pp.1794-804, 2016. ,
DOI : 10.3892/ijo.2016.3403
Zoledronic acid induces dose-dependent increase of antigen-specific CD8 T-cell responses in combination with peptide/poly-IC vaccine, Vaccine, vol.34, issue.10, 2016. ,
DOI : 10.1016/j.vaccine.2016.01.026
SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Paper presented at : 2016 -American Society of Clinical Downloaded by, pp.30-54, 2017163-08. ,